CKD is global public health concern with more than 1 million cases per year in India. It is a condition in which Kidneys are damaged and causes edema. Boerhaavia diffusa is a species of flowering plant belonging to the family of Nyctaginaceae. It is well known as Mookiratai, Punarnava, Putpagam, Rathaputpika. It is traditionally given for edema, intestinal colic, kidney disorders, cough, haemorrhoids etc. This investigation will look into the mechanics of Boerhaavia diffusa on CKD through network pharmacology and molecular docking by identifying the compounds of the herb and relevant targets related to CKD which has highest binding affinity by protein ligand interaction. Multiple bioinformatics tools and online databases were used to obtain relevant targets of Boerhaavia diffusa on CKD. In the study of molecular docking, Autodock 2.4.2 software was used to determine the binding mode and interaction between the key active compounds of Boerhaavia diffusa and hub proteins. The molecular docking showed that Boerhavinone O, sitosterol were the key compounds which showed highest binding affinity against the ligand model p53, ABCG2, BACE1. The results predicted and verified the potential targets of Boerhaavia diffusa on CKD from a holistic perspective and paved way for further preclinical and clinical studies of BD (Boerhaavia diffusa). BD can become novel promising Siddha drug in the treatment of CKD

Boerhaavia diffusa, CKD, Molecular docking, Boerhavinone, Sitosterol, ABCG2, p53, BACE1

Based on the outcomes of the computational study, it was determined that chemicals found in Boerhaavia diffusa, such as Boerhavinone O and sitosterol, significantly inhibit ABCG2 and thereby renal urate under secretion and induced hyperuricemia causing CKD can be prevented. BACE1, p53- it is a potential tumor suppressor and plays a critical role in AKI (Acute kidney injury) occurrence and progression of Chronic Kidney Disease (CKD). Sitosterol showed the highest binding affinity against ABCG2 and p53. However, it showed limited expression against BACE1. Boerhavinone O has the highest binding affinity against BACE1 followed by ABCG2 but has limited expression against p53. As there is no standard drug administered in the treatment of CKD, the Binding affinity of the ligand and target are studied and concluded. Further toxicity, Pre-clinical, and clinical studies are to be done to prove its efficacy against potential targets. Thereby formulations including Boerhaavia diffusa may have promising activity against CKD

Amirthavarshini A., T. Thiyagasundaram and S. Mathukumar (2023). Boerhaavia diffusa Linn. (Mookiratai) in the Treatment of Chronic Kidney Disease (CKD): A Network Pharmacology based Approach and Molecular Docking Studies. Biological Forum – An International Journal, 15(3a): 15-22.